作者
Paolo Palmisciano, Ali S Haider, Chibueze D Nwagwu, Waseem Wahood, Kenny Yu, Chibawanye I Ene, BARBARA J O’BRIEN, Salah G Aoun, Aaron A Cohen-Gadol, Tarek Y El Ahmadieh
发表日期
2021/11/1
来源
Anticancer research
卷号
41
期号
11
页码范围
5333-5342
出版商
International Institute of Anticancer Research
简介
Background/Aim
Leptomeningeal disease (LMD) is a debilitating complication of advanced malignancies. Immune-checkpoint inhibitors (ICIs) may alter disease course. We analyzed the role and toxicity of ICIs in LMD. Materials and Methods
We systematically reviewed the literature reporting on outcome data of patients with LMD treated with ICIs. Results
We included 14 studies encompassing 61 patients. Lung-cancer (44.3%), breast-cancer (27.9%), and melanoma (23.0%) were the most frequent primary tumors. Median duration of ICI-treatment was 7-months (range=0.5-58.0): pembrolizumab (49.2%), nivolumab (32.8%), ipilimumab (18.0%). Radiological responses included complete response (33.3%), partial response (12.5%), stable disease (33.3%), progressive disease (20.8%). Twenty-two patients developed ICI-related adverse-events, mild (100%) and/or severe (15.6%). Median progression-free and …学术搜索中的文章
P Palmisciano, AS Haider, CD Nwagwu, W Wahood… - Anticancer research, 2021